Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    

Reducing Surgical Site Infections in Orthopedic & Other Surgeries

Dr. Robert M. Harris

During my long career as an orthopedic trauma surgeon for civilian and military patients, I've seen the significant negative impact of surgical site infections (SSIs) on patient outcomes and healthcare costs. For civilian patients, SSI rates can be up to 2 percent for Type 1 open fractures and up to 50 percent for Type 3. For military patients with trauma wounds, infection rates can be as high as 77 percent. These infections pose a substantial burden in terms of increased morbidity and mortality, as well as resource demand on the healthcare system.

U.S. data from the Centers for Disease Control and Prevention (CDC) indicate an average of 1.5 million SSIs per year, with a mean direct cost per case of $20,785 and a total burden of some $3.3 billion annually. In the case of periprosthetic joint infection, per-case costs can rise in excess of $100,000. This SSI burden includes an additional 11.2 days of ICU care per case.

Moreover, insurers have increasingly labelled SSIs as "never events," meaning that the facility will receive reduced or no compensation for resolving these cases. The cost of treating the SSI comes directly out of a facility's bottom line. Johns Hopkins conducted an analysis on 2007-10 data and found that preventing a single SSI could yield a net saving of over $34,000.

Those analyses all occurred well before the COVID-19 pandemic began to overload and overwhelm healthcare systems worldwide. Clearly, this extra burden poses a substantial risk to patients, caregivers and healthcare systems already under strain. It is critical to identify novel techniques and technologies to help alleviate the problem.

Treatment options for SSIs are generally either pharmacologic (antibiotics) or invasive (surgical debridement, irrigation and stabilization), yet have widely varying degrees of success. Both risk factors and predictors of success are multivariate and include pathogen(s) present, patient comorbidities, patient socioeconomic status and timing to detection and intervention. No single factor can predict whether a patient will develop or recover from an SSI. Therefore, a multi-pronged approach is warranted.

When pharmacotherapy alone is deemed insufficient, a common approach is open irrigation of the wound. The choice of irrigant has been hotly debated in scientific and clinical circles, and most traditional approaches include antibiotics (which biologically disrupt microflora) or antiseptics/detergents (which chemically or mechanically disrupt microflora). Each offers advantages and disadvantages; for example, antibiotics generally have lower host toxicity but offer differential impact on various microbiological species and risk formation of biological resistance. In 2020, the FDA requested voluntary market withdrawal of bacitracin for injection into irrigation solutions because of safety concerns and extremely limited use in pediatric pneumonia, its only approved indication. Antiseptics and detergents can offer broad spectrum coverage with low risk of resistance but potentially damage host tissues. A more nuanced approach may be useful in both balancing microbial susceptibility and secondary tissue injury.

One important factor in removing microbial contamination -- and hence resolving infections -- is whether the population has been able to form a biofilm in the site. Known since the 1970s, biofilms are now widely understood to form a protective niche for microbes in a wide variety of environments. In brief, microbes can accrete on a surface (ranging from a speck of dust to a biological surface to a petroleum pipeline) and synthesize extracellular polymeric substance (EPS) -- a complex milieu of polysaccharides, proteins, lipids and nucleic acids, cross-linked by metal ions. This protective EPS layer defends the colony from immune, antibiotic and antiseptic attack.

The challenges posed by biofilm-based SSIs, and the limitations of other treatment options, are why I'm excited to lead a U.S. clinical trial to test the efficacy of XPERIENCE™, a new no rinse antimicrobial solution that received FDA clearance in April. Developed by medical technology company Next Science, XPERIENCE is based upon Next Science's proprietary XBIO™ Technology, which takes an innovative approach to solving the problem of bacterial biofilms. The unique, non-toxic technology attacks and deconstructs the structure of the biofilm by removing the metal ions that hold the EPS together. This exposes the bacteria within the biofilm, making them more vulnerable to eradication. Bacteria that are enveloped within the XBIO Technology are then destroyed by the combination of a surfactant and high osmotic imbalance across the bacterial cell wall. XBIO Technology's broad-spectrum efficacy helps defend from biofilm reformation, reducing the rate of reoccurrence by over 100X. Due to this unique mechanism of action, there is no known resistance to XBIO Technology.

The trial, the TIFRAX (Tibial Fracture) Study, is a randomized, controlled, double-blinded, prospective study to evaluate the efficacy of XPERIENCE in helping decrease wound bioburden and surgical site infections. It will also evaluate whether XPERIENCE can improve post-operative outcomes when used as adjunct treatment to standard of care in patients undergoing tibial fracture repair. Enrolment in the 30-patient, 90-day study is already underway.

Robert M. Harris, MD is a board-certified orthopedic surgeon based in Columbus, Ga., where he is program director for the Jack Hughston Memorial Hospital Orthopedic Residency Program and co-director of the Hughston Orthopedic Trauma Fellowship for the Hughston Clinic at Midtown Medical Center. Harris attended the COS annual meeting in Nashville from Nov. 3-6 as a guest of Next Science, for whose XPERIENCE product he is currently leading a U.S. clinical trial.

Dr. Robert Harris, Hughston Clinic

XPERIENCE by Next Science


Related Articles:

Recent Articles

Tivity Health Takes Meaningful Steps to Keep Seniors Engaged, Connected

At first glance, SilverSneakers might appear to be 'just' a fitness class ... but dig a bit deeper, and it's clear this class is actually a community keeping participants active and engaged.

Read More

AMA Adopts Policy to Combat Public Health Disinformation by Health Care Professionals

New policy aims to address spread of rampant disinformation amid COVID-19 pandemic

Read More

AMA Adopts Policy Aimed at Strengthening U.S. Public Health Infrastructure, Opposing Limits Placed on Public Health Officials

New policy calls for consistent, sustainable funding, a robust public health workforce, and data modernization

Read More

Managing Risk of Cyber Incidents

Cyber threats are here to stay -- and they continue to be one of the topics keeping senior management up at night. With breaches and ransomware attacks still occurring at high rates, the healthcare industry continues to be significantly impacted.

Read More

American Cancer Society, Meharry Team Up to Change the Narrative

Meharry Medical College is one of four HBCUs partnering with the American Cancer Society.

Read More

Navigating Cancer Care

Nashville startup Thyme Care is proving to be an innovator in the cancer navigation space.

Read More

ONcology Rounds

New treatments, research and leadership - Middle Tennessee has a lot going on in oncology care.

Read More

Reducing Surgical Site Infections in Orthopedic & Other Surgeries

Insights from a leading orthopedic trauma surgeon who recently visited Nashville for the Clinical Orthopaedic Society (COS) 2021 annual meeting in early November. Robert Harris, MD serves as First President-Elect for the COS.

Read More

HealthStream Preps the Workforce to Battle the Opioid Epidemic

Fanning the flames of emotional and physical pain, the global COVID-19 pandemic has added fuel to opioid use, driving the epidemic to new heights.

Read More

Fighting Addiction on All Fronts

Substance use disorder knows no racial, economic, sexual orientation, age or gender boundaries. Fighting it requires a concerted effort on all fronts.

Read More

Email Print



Antimicrobial Solution, Biofilm, Hughston Clinic, Next Science, Orthopaedic, Orthopedic, Robert Harris, SSI, Surgical Site Infection, Trauma Surgeon, XBIO Technology, XPERIENCE
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: